ID-iPS7
HUJIi005-A
General
Cell Line |
|
hPSCreg name | HUJIi005-A |
Cite as: | HUJIi005-A (RRID:CVCL_E4D0) |
Alternative name(s) |
ID-iPS7
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 20th April 2024 |
User feedback | |
Provider |
|
Generator | Hebrew University of Jerusalem (HUJI) |
Owner | Hebrew University of Jerusalem (HUJI) |
External Databases |
|
BioSamples | SAMEA115345296 |
Cellosaurus | CVCL_E4D0 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Ethnicity | Ashkenazi/sephardic jews |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed. |
Disease associated phenotypes |
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA115345297 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Bruria.BenZeev@sheba.health.gov.il |
Is there other documentation provided to the donor for consenting purposes? | No |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Mononuclear cells collected from peripheral blood.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
|
|||
SOX2 |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
|
|||
SSEA-4 |
Yes |
|
|
|||
TRA 1-60 |
Yes |
|
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46(x,y)
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.